ЭЛИ-НейроТЕСТ-12

ELI-N-TEST (ELI‑NeuroTest‑12) profiles IgG autoantibodies to 12 neurospecific antigens and neurotransmitter receptor systems to assess nervous system involvement. The assay supports early recognition of tissue injury signatures affecting neurons, glia, myelin, and key neurochemical pathways and can complement neurologic evaluation and longitudinal monitoring. This multiparameter ELISA is used as an adjunct to clinical assessment when central or peripheral nervous system disease is suspected or when ongoing risk to neural tissue is anticipated. Results are interpreted in context and are not diagnostic in isolation.

This test quantifies IgG autoantibodies directed against cellular components relevant to nervous system structure and function using a multiparametric ELISA platform. Natural IgG autoantibodies participate in homeostatic clearance and cellular regulation in healthy individuals. Shifts in selected autoantibody levels—either increases or decreases—can accompany pathologic processes affecting specific organs or tissues, including neural elements, and may emerge before overt clinical manifestations. Results serve a prognostic and contextual role and require expert interpretation alongside clinical data. The panel encompasses 12 targets that reflect complementary aspects of neural biology: IgG to NF‑200 (marker of axonal change); IgG to glial fibrillary acidic protein (astroglial change); IgG to S100B (altered tissue growth and differentiation; disturbances in neuropsychiatric processes); IgG to myelin-associated proteins (changes in myelin sheaths of nerve fibers); IgG to voltage‑gated calcium channels (neuromuscular junction alterations); and IgG to neurotransmitter systems including nicotinic acetylcholine, glutamate, GABA, dopamine, serotonin, and opioid receptors, as well as beta‑endorphin. Together, these markers outline the status of neurons, glial cells, nerve fibers, and major neuromodulatory pathways. Results are reported as antibody levels with a graphical profile. Values above the reference interval can indicate existing or emerging tissue changes related to injury. Values below the reference interval can indicate chronic processes or regression of an acute inflammatory response. This assay does not, by itself, establish a diagnosis or direct therapy; interpretation is performed by a clinician familiar with ELI‑test methodology.